Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biofrontera (BFRI) Research & Development (2023 - 2025)

Biofrontera has reported Research & Development over the past 3 years, most recently at $787000.0 for Q4 2025.

  • For Q4 2025, Research & Development rose 0.51% year-over-year to $787000.0; the TTM value through Dec 2025 reached $3.7 million, up 77.89%, while the annual FY2025 figure was $3.7 million, 78.03% up from the prior year.
  • Research & Development for Q4 2025 was $787000.0 at Biofrontera, down from $854000.0 in the prior quarter.
  • Over five years, Research & Development peaked at $1.2 million in Q1 2025 and troughed at $11000.0 in Q2 2023.
  • A 3-year average of $535000.0 and a median of $669000.0 in 2024 define the central range for Research & Development.
  • On a YoY basis, Research & Development climbed as much as 7000.0% in 2025 and fell as far as 0.51% in 2025.
  • Year by year, Research & Development stood at $33000.0 in 2023, then surged by 2272.73% to $783000.0 in 2024, then rose by 0.51% to $787000.0 in 2025.
  • Business Quant data shows Research & Development for BFRI at $787000.0 in Q4 2025, $854000.0 in Q3 2025, and $870000.0 in Q2 2025.